Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory analysis of colonic mucosal changes with tofacitinib in moderate to severe ulcerative colitis
2016-002691-27Phase 3Completed
- Sponsor
- Academic Medical Center
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib in autoimmune colitis, sponsored by Academic Medical Center. Primary endpoints: Change in histological inflammation at week 8 and Immune cell infiltration and mRNA expression in colonic mucosa. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-002691-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002691-27.